Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
Date:12/12/2011

els of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days. NUEDEXTA is contraindicated in patients with a known hypersensitivity to its components.

NUEDEXTA may cause serious side effects, including possible changes in heart rhythm. NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, in patients with heart failure as well as patients with, or at risk of, complete atrioventricular (AV) block, unless the patient has an implanted pacemaker.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk of QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, weakness, swelling of feet and ankles, urinary tract infection, flu, elevated liver enzymes, and flatulence.

NUEDEXTA may cause dizziness. Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls.

Patients should take NUEDEXTA exactly as prescribed. Patients should not take more than 2 capsules in a 24-hour period, make sure that there is an approximate 12-hour interval between doses, and not take a double dose after they miss a dose.

These are not all the risks from use of NUEDEXTA. For additional important safety information about NUEDEXTA, please see the full Prescribing Informat
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
2. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
3. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
4. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
6. Avanir Pharmaceuticals to Participate in Two Investor Conferences
7. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
8. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
9. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
10. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
11. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... In conjunction with DURECT Corporation,s (Nasdaq: ... release, you are invited to listen to the conference ... on Thursday, August 7, 2014 at 4:30 pm Eastern ... audio webcast of the presentation will be available by ... "Investor Relations."  If you are unable to participate during ...
(Date:7/30/2014)... , July 30, 2014 The ... Care Pharmacy (AMCP) last evening expressed support for ... the Joint Commission of Pharmacy Practitioners (JCPP).  As ... organizations over a two-year period to develop a ... pharmacists.  "Pharmacists are fast becoming ...
(Date:7/30/2014)... 2014 Research and Markets has announced the ... to 2019" report to their offering. ... grow at a lower CAGR in developed countries; however, it is ... China , India , and ... The growth of the hematology analyzers and reagents market is driven ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2Hematology Analyzers & Reagents Market - Forecasts to 2019 2
... Georgia has announced the details of their Prostate Cancer ... Georgia in January.  These courses enable the public to become ... All Prostate Cancer Lecture Series seminars are offered free to ... p.m. followed by a lecture at 5:30 p.m. Classes are ...
...  A group of 22 bipartisan House Members yesterday wrote ... asking the agency to stop their prepayment review project ... beneficiaries. The lawmakers, who included Rep. Bill ... job losses, restricted access to mobility equipment for Medicare ...
Cached Medicine Technology:Radiotherapy Clinics of Georgia Present Prostate Cancer Lecture Series 2Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries 2Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries 3
(Date:7/30/2014)... AR (PRWEB) July 30, 2014 Throughout ... their patients with free oral cancer screenings. Using a ... will work to detect the disease in its early ... lips, tongue, cheek, mouth, sinuses, throat and other areas ... Cancer Institute’s Surveillance, Epidemiology, and Ends Results (SEER) program, ...
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... who want to help their preschooler shed excess pounds may ... Youngsters whose parents joined them in a supervised behavioral ... enrolled in a traditional child-only program (an average difference of ... benefited, losing almost 15 pounds over two years, according to ...
(Date:7/30/2014)... York (PRWEB) July 30, 2014 The ... brain bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... blood thinner, Bernstein Liebhard LLP reports. According to the ... the District of Vermont on July 25th, the decedent ... he suffered an irreversible brain bleed that ultimately led ...
(Date:7/30/2014)... phrase "we caught it early" is possibly the best ... a cancer diagnosis. Combating cancer in its earliest stages, ... of the body, gives patients the best chances of ... and other forms of cancer are touted for saving ... cancer screenings as a precautionary measure, especially for high-risk ...
Breaking Medicine News(10 mins):Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... still too early to say that phthalates actually ... (HealthDay News) -- Common chemicals found in plastic toys ... breasts in boys, preliminary research suggests. , The ... adds fuel to the debate over these chemicals, called ...
... up within a week of getting news, researchers say ... can put newly diagnosed prostate cancer patients at increased ... has found. , Researchers analyzed data on 168,584 Swedish ... Of those men, 10,126 (6 percent) experienced a cardiovascular ...
... , LEXINGTON, Ky., Dec. ... confirmed today that VHGI Gold (a wholly owned operating subsidiary ... VHGI advisory board to assist with bringing the Treasure Gulch ... possible. Additionally, the company is informing interested shareholders and related ...
... , , NEW YORK, Dec. ... research report is available in its catalogue: , ... - Market Forecasts to 2015, Competitive Benchmarking, Product ... http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html , Summary , The ...
... Ill. and CHENNAI, India, Dec. 15 Hospira, Inc. ... generic injectable pharmaceuticals, and Orchid Chemicals & Pharmaceuticals Ltd. ... and among the top-five generic beta-lactam antibiotics manufacturers globally, ... generic injectable finished-dosage form pharmaceuticals business for approximately $400 ...
... are often treated with hormones, but when the tumours ... vessels, reveals a thesis from the Sahlgrenska Academy, at ... way for new treatments for hormone-resistant prostate cancer. ... prostate cancer has spread, most patients are given hormone ...
Cached Medicine News:Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 2Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 3Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 4Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 23Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 2Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 3Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 4Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 5Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 6Health News:More blood vessels in hormone-resistant prostate tumors 2
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
... Maximize blood flow and minimize pain ... the safety-engineered BD Microtainer Quikheel Lancet. ... surgical blade providing a precise and ... retracts into its casing, helping to ...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
Medicine Products: